Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 200 of 248 entries
View as:

NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

Phase: N/A Priority: Normal
NCT ID: NCT06405490 Org: User:
Start: 04/17/24 End: 12/30/26 Due: 12/30/27

Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy

Phase: N/A Priority: Normal
NCT ID: NCT05777824 Org: User:
Start: 01/01/23 End: 12/30/27 Due: 12/30/28

Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06417892 Org: User:
Start: 04/15/24 End: 12/30/26 Due: 12/30/27

Safety and Feasibility of Laparoscopic Intracorporeal Anastomosis for Colorectal Surgery- A Multiple Center Real World Study

Phase: N/A Priority: Normal
NCT ID: NCT05911152 Org: User:
Start: 01/01/16 End: 01/01/25 Due: 01/01/26

Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJ

Phase: N/A Priority: Normal
NCT ID: NCT06808971 Org: User:
Start: 02/05/25 End: 12/31/27 Due: 12/31/28

Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT06793813 Org: User:
Start: 01/23/24 End: 12/30/26 Due: 12/30/27

A Multicenter Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06791161 Org: User:
Start: 01/19/25 End: 01/18/35 Due: 01/18/36

Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05540145 Org: User:
Start: 05/01/22 End: 12/31/23 Due: 12/31/24

Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC

Phase: N/A Priority: Normal
NCT ID: NCT06170710 Org: User:
Start: 12/01/23 End: 11/30/27 Due: 11/30/28

Inhaled mRNA Tumor-associated Antigen Dry Powder Vaccine in Advanced Lung Cancer and Lung Metastasis of Solid Tumors.

Phase: N/A Priority: Normal
NCT ID: NCT06928922 Org: User:
Start: 02/24/25 End: 02/24/28 Due: 02/24/29

PLATFORM Study of Precision Medicine for Rare Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04423185 Org: User:
Start: 08/15/20 End: 07/01/28 Due: 07/01/29

Perioperative Analgesia Modes in Minimally Invasive Esophagectomy

Phase: N/A Priority: Normal
NCT ID: NCT05504265 Org: User:
Start: 10/10/22 End: 12/20/25 Due: 12/20/26

The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis

Phase: N/A Priority: Normal
NCT ID: NCT05431504 Org: User:
Start: 06/30/22 End: 12/31/27 Due: 12/31/28

Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy

Phase: N/A Priority: Normal
NCT ID: NCT06667622 Org: User:
Start: 05/29/24 End: 07/20/26 Due: 07/20/27

An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06038461 Org: User:
Start: 09/15/23 End: 09/15/26 Due: 09/15/27

Multivisceral Radical Resection for Surgical T4b Colorectal Cancer: Propensity Score-matched Study Comparing the the Laparoscopic and Open Approaches

Phase: N/A Priority: Normal
NCT ID: NCT05707598 Org: User:
Start: 01/01/23 End: 01/11/23 Due: 01/11/24

Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06197581 Org: User:
Start: 01/12/24 End: 01/15/27 Due: 01/15/28

IORT Versus CCRT for Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02981641 Org: User:
Start: 12/31/15 End: 12/31/18 Due: 12/31/19

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation

Phase: N/A Priority: Normal
NCT ID: NCT04500717 Org: User:
Start: 10/31/20 End: 10/31/23 Due: 10/31/24

A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults

Phase: N/A Priority: Normal
NCT ID: NCT06761417 Org: User:
Start: 02/01/25 End: 02/01/28 Due: 02/01/29

Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06926751 Org: User:
Start: 04/07/25 End: 09/01/27 Due: 09/01/28

A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06074484 Org: User:
Start: 09/10/23 End: 08/10/25 Due: 08/10/26

Jianzhong Qushi in Chronic RRI

Phase: N/A Priority: Normal
NCT ID: NCT06837597 Org: User:
Start: 03/15/25 End: 01/31/29 Due: 01/31/30

Ivonescimab Plus Chemotherapy in Patients with Initially Unresectable Colorectal Cancer Liver Metastases

Phase: N/A Priority: Normal
NCT ID: NCT06848842 Org: User:
Start: 03/01/25 End: 06/30/27 Due: 06/30/28

Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06644352 Org: User:
Start: 07/01/22 End: 07/01/27 Due: 07/01/28